• Lōkahi Therapeutics, a GlucoTrack subsidiary, began an initial GMP manufacturing campaign for LT-100, a pure honeybee venom biologic for knee osteoarthritis pain.
• Clinical trial supply is intended to support the next clinical and regulatory milestones for LT-100.
• Program targets a shift to one subcutaneous injection per visit from 15 intradermal injections used in earlier efficacy trials.
• First patient enrollment is expected later this year, subject to manufacturing completion, quality reviews, clinical readiness, regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GlucoTrack Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260825097954) on August 25, 2026, and is solely responsible for the information contained therein.